Aadi Bioscience (NASDAQ:AADI) Releases Earnings Results, Misses Expectations By $0.36 EPS

Aadi Bioscience (NASDAQ:AADI) issued its quarterly earnings data on Tuesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.36), Zacks reports. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%.

Aadi Bioscience Trading Down 2.4 %

Aadi Bioscience stock traded down $0.05 during mid-day trading on Tuesday, hitting $2.05. The stock had a trading volume of 62,875 shares, compared to its average volume of 244,689. The firm has a market capitalization of $50.63 million, a P/E ratio of -0.90 and a beta of 0.68. The firm’s 50 day moving average is $2.73 and its 200 day moving average is $2.40. Aadi Bioscience has a one year low of $1.21 and a one year high of $3.81.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.